BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

CStone Submits EMA Application to Expand Sugemalimab Use in Stage III Lung Cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submiss...

March 25, 2025 | News

Shanghai ArkBio Completes Phase III Trial of AK0901 for Pediatric ADHD in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of a...

March 25, 2025 | News

Alamar Biosciences Launches NULISAseq Mouse Panel 120 to Power Precision Biomarker Discovery in Preclinical Research

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce the launch of the NULISAseq M...

March 26, 2025 | News

Sermonix and Regor Therapeutics Forge Strategic Alliance to Advance Targeted Therapies for Metastatic Breast Cancer

Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mB...

March 25, 2025 | News

Menarini Group, Stemline, and VisualDx Join Forces to Boost Early Detection of BPDCN Using AI-Driven Skin Imaging

BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 ...

March 21, 2025 | News

Telix Secures FDA Approval for Gozellix® to Expand PSMA-PET Imaging Access in Prostate Cancer

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administrat...

March 21, 2025 | News

Formosa Pharmaceuticals and Cipla Sign Multi-Regional Licensing Deal for Ophthalmic Suspension APP13007

Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clob...

March 19, 2025 | News

SOPHiA GENETICS Surpasses Two Million Genomic Profiles Analyzed on AI-Powered Platform

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million...

March 19, 2025 | News

Akeso’s Penpulimab Secures NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National ...

March 18, 2025 | News

Rona Therapeutics Secures FDA IND Clearance for RN0361, Advancing RNAi Therapy for Severe Hypertriglyceridemia

Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Dru...

March 18, 2025 | News

Innovent’s SYCUME® Becomes China’s First IGF-1R Antibody Approved for Thyroid Eye Disease

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

March 17, 2025 | News

Exicure Secures Australian Patent for Dual-Target Cancer Therapy Approach

Exicure, Inc. announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." ...

March 14, 2025 | News

Qureight and Remedy Cell Partner to Validate RC-0315’s Regenerative Potential in Idiopathic Pulmonary Fibrosis

Qureight Ltd, a Core Imaging Laboratory with deep-learning analytics, and Remedy Cell, a clinical-stage biopharmaceutical company focused on the developmen...

March 12, 2025 | News

Ascletis’ ASC47 Shows Promise as a Long-Acting, Muscle-Preserving Obesity Treatment in Phase Ib Study

ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and ...

March 12, 2025 | News

Stay Connected